Celgene to acquire Quanticel Pharmaceuticals in share purchase deal
Celgene Corp. has entered a share purchase agreement with Quanticel Pharmaceuticals Inc. and will acquire the company, Celgene announced on Monday. Read More »
Celgene Corp. has entered a share purchase agreement with Quanticel Pharmaceuticals Inc. and will acquire the company, Celgene announced on Monday. Read More »
Health system will utilize a number of Omincell's products Read More »
Education blog targeted toward professionals in the infusion nursing community Read More »
Alibaba Group Holding Ltd. on Tuesday announced it has reached a definitive agreement with Hong Kong Stock Exchange-listed Alibaba Health Information Technology Ltd. Read More »
Praxsyn Corp. on Tuesday announced that its wholly owned subsidiary, Mesa Pharmacy Inc., entered into a business associate agreement in January with Products for Doctors for marketing and other services. Read More »
According to a survey of 443 employers conducted by WorldatWork and underwritten by HealthMine, wellness programs aren’t being held accountable for lowering health care costs. Read More »
Actavis confirmed last week that it has filed an abbreviated new drug application with the U.S. Food and Drug Administration (FDA), requesting approval to market Ambrisentan, and has confirmed a patent challenge. Read More »
Daniel Soland joins biopharmaceutical company. Read More »
OptumRX, UnitedHealth Group’s pharmacy-care services business, and Catamaran Corp., a provider of pharmacy-benefit services and technology solutions, said on Monday that they have agreed to a merger. Read More »
Omnicell, Inc., announced on Wednesday that it will exhibit the addition of its automated medication cabinets with MACH4's modular robotic solutions at the European Association of Hospital Pharmacists until March 27. Read More »
MedImpact Healthcare Systems, Inc., an independent, trend-focused pharmacy benefit manager, on Monday announced it will be the first to deploy Fast Identity Online (FIDO) authentication for the health care industry. Read More »
ACADIA Pharmaceuticals said on Wednesday that Uli Hacksell has retired as CEO and from the board of directors, and that Steve Davis -- executive vice president, chief financial officer and chief business officer -- has been appointed interim CEO. Read More »
Parata Systems, a pharmacy technology solutions provider, said on Tuesday that it has appointed Emilie Ray to the Parata Board of Directors. "We are delighted Emilie has joined the board of directors," Parata CEO Tom Rhoads said. Read More »
Integra´s most recent version of its business automation tool, Logix, allows pharmacies to remove repetitive and time consuming procedures. Read More »
Omnicell, a provider of medication and supply management solutions to health care systems and pharmacies, said on Thursday that it signed an agreement to purchase MACH4 Pharma Systems, which supplies highly automated medication management systems to over 1,000 retail hospitals and pharmacies in Europe, China and the Middle East. Read More »
Recent data from the annual Truven Health Analytics U.S. Benchmarks and Trends reports for employers and health plans predict that employee out-of-pocket costs will experience double-digit growth, and commercial-payer costs will grow at a more modest rate. Read More »
Amgen said on Wednesday that its Biologics License Application (BLA) for talimogene laherparepvec will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and the Cellular, Tissue and Gene Therapies Advisory Committee. Read More »
Rite Aid and Envision Pharmaceutical Services (EnvisionRx) said on Wednesday that they have reached a final agreement in which Rite Aid will purchase EnvisionRX, a transaction valued at approximately $2 billion. Read More »
Genentech, a member of the Roche group, said on Friday that the U.S. Food and Drug Administration (FDA) approved Lucentis, the first eye medicine sanctioned to treat diabetic retinopathy (DR) with diabetic macular edema (DME). Read More »
Amgen’s Phase 3 study assessing the safety and effectiveness of biosimilar candidate ABP 501 versus Humira in patients with moderate to sever rheumatoid arthritis revealed positive results. Read More »